FindMyKOL
Clinical trialNCT02403310CompletedPhase 1Interventional

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment21AMLAcute Myeloid LeukemiaLeukemia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this study is to determine the safety of combining selinexor with daunorubicin and cytarabine. The maximal tolerated dose (MTD) of selinexor with daunorubicin and cytarabine will also be established.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Kendra Sweet, M.D.

    H. Lee Moffitt Cancer Center and Research Institute

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cytarabine →Daunorubicin →Selinexor →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Jun 2015
Primary completion
13 Sept 2016
Completion
1 Feb 2021
Last update posted
3 Oct 2022
Registered enrollment
21
Registry id
NCT02403310
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.